Molecular structures of the beta2-adrenergic receptor were successfully captured by Brian Kobilka, providing a critical advancement in understanding G protein-coupled receptors. This accomplishment addressed a significant challenge in X-ray crystallography, as these proteins were notoriously difficult to isolate. His research provided a foundation for mapping other receptors, which serve as primary targets for modern pharmaceutical therapeutic interventions.
Academic Foundation
Raised in Little Falls, Minnesota, Kobilka attended St. Mary's Grade School and Little Falls High School. He pursued undergraduate studies at the University of Minnesota Duluth, focusing on biology and chemistry, before earning his M.D. cum laude from the Yale University School of Medicine. Following an internal medicine residency at the Barnes-Jewish Hospital in St. Louis, he joined Robert Lefkowitz at Duke University as a postdoctoral fellow to begin his work on receptor cloning.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →Structural Biology Breakthroughs
Kobilka joined Stanford University in 1989, where his laboratory concentrated on the complex structure of G protein-coupled receptors. Previously, only rhodopsin had been mapped at high resolution. His team's success in determining the architecture of the beta2-adrenergic receptor enabled a cascade of subsequent discoveries in the field. This research, supported by grants such as the Javits Neuroscience Investigator Award, transformed the ability of scientists to visualize how these signaling proteins operate at a molecular level.
Professional Recognition and Global Initiatives
His scientific contributions earned him the 2012 Nobel Prize in Chemistry, shared with Robert Lefkowitz. Beyond his academic appointments, Kobilka has been recognized with the John J. Abel Award, the Julius Axelrod Award, the Mendel Medal, and the Louis and Artur Lucian Award. In 2017, he established the Kobilka Institute of Innovative Drug Discovery in Shenzhen, China, and he remains a co-founder of the biotechnology firm ConfometRx.
Fast facts
- Born: 1955, Little Falls
- Citizenship: United States
- Education: University of Minnesota Duluth, Yale School of Medicine, Duke University
- Primary Field: Crystallography
- Nobel Prize in Chemistry: 2012
- Current Employer: Stanford University School of Medicine
- Memberships: National Academy of Sciences, Royal Irish Academy
Questions readers ask
What is Brian Kobilka's primary research contribution?
He is recognized for determining the molecular structure of G protein-coupled receptors, particularly the beta2-adrenergic receptor.
With whom did he share the 2012 Nobel Prize?
He shared the Nobel Prize in Chemistry with Robert Lefkowitz.
Achievements
- Nobel Prize in Chemistry — 2012
- Mendel Medal — 2015
- Held posts at Duke University, Stanford University School of Medicine and Stanford University
- Fields: crystallography
